Étiquette : CBD

Short- and Long-Term Effects of Cannabis on Headache and Migraine, Carrie Cuttler et al., 2019

Short- and Long-Term Effects of Cannabis on Headache and Migraine Carrie Cuttler, Alexander Spradlin, Michael J. Cleveland, and Rebecca M. Craft Journal of Pain, 2019. doi : 10.1016/j.jpain.2019.11.001   Highlights  Headache and migraine ratings were reduced by nearly 50% after using cannabis  Men reported larger reductions in headache after cannabis use than women  Cannabis concentrates were related to larger reductions in headache than flower  Evidence for tolerance to effects of cannabis on headache and migraine was detected  Evidence for medication overuse headache was not detected   Abstract Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to [...]

Lire la suite

Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal, Francisco Navarrete et al., 2018

Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226   BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]

Lire la suite

Cannabis is Not a Suitable Human Coronavirus Treatment, Marc Moulin, Rxleaf.com, 2020

Cannabis is Not a Suitable Human Coronavirus Treatment Marc Moulin March 20, 2020 https://www.rxleaf.com/cannabis-not-good-human-coronavirus-treatment/ Using cannabis as a human coronavirus treatment may make symptoms worse.  Cannabis is great for a lot of things. For example, many physical conditions see symptom abatement with cannabinoid treatment. Additionally, there is adequate, and in some cases, strong, scientific evidence to support consuming cannabis for therapeutic relief. Unfortunately, fighting off influenza-like viruses is not one of them. It’s important to note that there is absolutely no evidence to suggest that cannabis is an effective human coronavirus treatment. On the contrary, researchers from Michigan State University provide recent evidence to demonstrate potentially harmful [...]

Lire la suite

Cannabis and Coronavirus : What Cannabis Patients Want to Know, Rxleaf.com, February 17, 2020

Cannabis and Coronavirus : What Cannabis Patients Want to Know Jennifer Grant https://www.rxleaf.com/cannabis-and-coronavirus-what-cannabis-patients-want-to-know/ February 17, 2020 There is evidence that cannabis can reduce viral load in HIV, can it help COVID-19 patients? At the time of writing, there were 69, 287 confirmed cases of the coronavirus and 1670 deaths. With the rapid escalation of the outbreak, these numbers will surely be outdated by the time of publication. With several regions heading into states of emergencies, including quarantine, nervous travelers are looking for anti viral herbs to reduce the chance of infection. Patients have asked us: What about cannabis? There have been rumors about successful treatments for coronavirus, [...]

Lire la suite

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial, Kerri A. Schoedel et al., 2018

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027   a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]

Lire la suite

Autorisation Temporaire Exceptionnelle d’Utilisation compassionnelle du cannabis médical, Laurent Appel, ASUD, 26 mars 2020

Autorisation Temporaire Exceptionnelle d'Utilisation compassionelle du cannabis médical Laurent Appel (conseil en communication spécialisé en réduction des risques) 06.81.54.10.96 mailto : laurent.appel@asud.org relayé par    www.Principesactifs.org, 26/03/2020   La chaine de soins et de médicament est en tension maximum. Le rôle de chacun est de détecter les failles actuelles et surtout futures pour éviter d'ajouter encore de la tension et faire tout sauter.Le cannabis médical peut jouer un rôle majeur tant comme solution thérapeutique alors que qon manque sera un facteur important de tensions.   D'un point de vue médical, il va manquer aux patients déjà traités clandestinement et surtout au million de patients en automédication. Nous risquons donc avoir [...]

Lire la suite

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential, C. Michael White, 2019

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387   Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]

Lire la suite

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches, Marcel O. Bonn-Miller et al., 2018

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730   ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]

Lire la suite

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, Andreza B. Sonego et al., 2016

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042   Highlights  Cannabidiol (CBD) attenuated haloperidol-induced catalepsy.  CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol.  CBD effects were blocked by 5-HT1A receptor antagonist.   Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]

Lire la suite

Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users, Katherine A. Belendiuk et al., 2015

Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032   a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]

Lire la suite